{"id":1703,"date":"2017-03-15T10:44:06","date_gmt":"2017-03-15T09:44:06","guid":{"rendered":"https:\/\/colox.ch\/?p=1703"},"modified":"2018-03-19T11:43:14","modified_gmt":"2018-03-19T10:43:14","slug":"novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test","status":"publish","type":"post","link":"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/","title":{"rendered":"Novigenix Signs Distribution Agreement with Dr Risch Medical Laboratory to Access Swiss German Market for Colox\u00ae, its blood based colorectal cancer test"},"content":{"rendered":"<h4><strong>Agreement significantly increases access to Colox\u00ae in<br \/>\nSwitzerland and Liechtenstein<\/strong><\/h4>\n<p>LAUSANNE, Switzerland, March 15, 2017 \u2013 Novigenix SA today announced a<br \/>\ncommercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the<br \/>\nearly detection of colorectal cancer (CRC). Dr Risch is a successful and science-driven clinical<br \/>\nlaboratory organization with a strong foothold in the Swiss German market and Liechtenstein.<br \/>\nThe agreement significantly enhances Novigenix\u2019s footprint in the Swiss market. In 2014, the<br \/>\nCompany closed a similar agreement with Unilabs to target the French Swiss market.<br \/>\nNovigenix continues to seek commercialization agreements for Colox to cover the entire Swiss<br \/>\nmarket, while also intensifying its efforts for international distribution, in particular in other<br \/>\nEuropean markets.<br \/>\nStarting in March 2017, and with Colox as its flagship product, Dr Risch intends to launch a full<br \/>\nrange of diagnostic colorectal cancer services, including gold-standard fecal immunochemical<br \/>\ntests (FIT) to detect blood in stool.<br \/>\nProf. Dr. Lorenz Risch. Chief Medical Officer of Risch, said: \u201cColox has all the hallmarks of a<br \/>\nconvenient test for colorectal cancer and can serve as a valuable tool in the physician\u2019s arsenal<br \/>\nto identify cases with colorectal cancer. Colorectal cancer places a huge burden on people\u2019s<br \/>\nlives and on our healthcare system. At Dr Risch we share Novigenix\u2019s ambition to increase<br \/>\nawareness for CRC and to position Colox as a tool for cancer prevention.\u201d<br \/>\nNicolas Demierre, COO of Novigenix SA, said: \u201cWe are delighted to have found in Dr Risch a<br \/>\nsolid and science-driven partner that is dedicated to help reduce cancer mortality through early<br \/>\ndetection of colorectal cancer and advanced polyps. Together with data from our ongoing,<br \/>\nprospective 1000-patient study PROSPEROS, we expect that our collaboration with Dr Risch<br \/>\nwill significantly contribute to our growing body of clinical evidence of Colox in routine medical<br \/>\npractice.\u201d<\/p>\n<p><strong>About colorectal cancer:<\/strong><br \/>\nColorectal cancer is the second leading cause of cancer mortality in Europe and North<br \/>\nAmerica. Current methods of detection of CRC are cumbersome and invasive, requiring<br \/>\nunpleasant preparation of the colon, or stool manipulation at home. As a result the majority of<br \/>\nindividuals at average risk resist testing and fail to be referred to potentially therapeutic or<br \/>\npreventative colonoscopy. In Switzerland alone this leads to 5 people dying every day from<br \/>\nthis largely preventable disease.<\/p>\n<p><strong>About Colox\u00ae:<\/strong><br \/>\nColox\u00ae is a proven molecular blood test that has been designed to support physicians in case<br \/>\nfinding of patients with CRC and adenomas for referral to colonoscopy. The test can support<br \/>\nthe healthcare community to significantly reduce mortality from colorectal cancer through early<br \/>\ndetection and intervention. Colox can be ordered by any physician in routine medical practice<br \/>\nto identify patients with adenomatous polyps and colorectal cancer.<\/p>\n<p><strong>About Dr Risch:<\/strong><br \/>\nDr Risch SA is science-driven, family-owned leader in laboratory testing in Switzerland and<br \/>\nLiechtenstein. Founded in 1970, Dr Risch today operates 13 clinical laboratories in all Swiss<br \/>\nregional language regions with privileged access to private, regional, and academic hospitals<br \/>\nand general practitioners. For more information please visit <a href=\"http:\/\/www.risch.ch\">www.risch.ch<\/a><\/p>\n<p><strong> About Novigenix SA:<\/strong><br \/>\nNovigenix SA is an innovative Swiss molecular diagnostics company focused on the<br \/>\ncommercialization of new blood tests for the early detection of cancer. Novigenix\u2019s products<br \/>\nrely on a new generation of predictive molecular signatures and state-of-the-art mathematical<br \/>\nanalytical models to provide new solutions for the early detection of cancer. For more<br \/>\ninformation please visit <a href=\"https:\/\/colox.ch\">www.novigenix.com<\/a><\/p>\n<p><a href=\"https:\/\/colox.ch\/wp-content\/uploads\/2017\/03\/Novigenix-Dr-Risch-Final-15032017.pdf\" target=\"_blank\" rel=\"noopener\"><strong>T\u00e9l\u00e9charger le PDF<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Agreement significantly increases access to Colox\u00ae in Switzerland and Liechtenstein LAUSANNE, Switzerland, March 15, 2017 \u2013 Novigenix SA today announced a commercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the early detection of colorectal cancer (CRC). Dr Risch is a successful and science-driven clinical laboratory organization with a strong foothold [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[],"class_list":["post-1703","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.6 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novigenix Signs Distribution Agreement with Dr Risch Medical Laboratory to Access Swiss German<\/title>\n<meta name=\"description\" content=\"Agreement significantly increases access to Colox\u00ae in Switzerland and Liechtenstein LAUSANNE, Switzerland, March 15, 2017. Novigenix SA today announced a commercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the early detection of colorectal cancer (CRC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novigenix Signs Distribution Agreement with Dr Risch Medical Laboratory to Access Swiss German\" \/>\n<meta property=\"og:description\" content=\"Agreement significantly increases access to Colox\u00ae in Switzerland and Liechtenstein LAUSANNE, Switzerland, March 15, 2017. Novigenix SA today announced a commercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the early detection of colorectal cancer (CRC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/\" \/>\n<meta property=\"og:site_name\" content=\"Colox\" \/>\n<meta property=\"article:author\" content=\"https:\/\/www.facebook.com\/mymiddlelife\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-03-15T09:44:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-03-19T10:43:14+00:00\" \/>\n<meta name=\"author\" content=\"Novigenix\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Novigenix\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/\"},\"author\":{\"name\":\"Novigenix\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/person\/b62de2e3f97aea1ffe3303259cbbb20a\"},\"headline\":\"Novigenix Signs Distribution Agreement with Dr Risch Medical Laboratory to Access Swiss German Market for Colox\u00ae, its blood based colorectal cancer test\",\"datePublished\":\"2017-03-15T09:44:06+00:00\",\"dateModified\":\"2018-03-19T10:43:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/\"},\"wordCount\":581,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/colox.ch\/de\/#organization\"},\"articleSection\":[\"Communiqu\u00e9 de presse\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/\",\"url\":\"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/\",\"name\":\"Novigenix Signs Distribution Agreement with Dr Risch Medical Laboratory to Access Swiss German\",\"isPartOf\":{\"@id\":\"https:\/\/colox.ch\/de\/#website\"},\"datePublished\":\"2017-03-15T09:44:06+00:00\",\"dateModified\":\"2018-03-19T10:43:14+00:00\",\"description\":\"Agreement significantly increases access to Colox\u00ae in Switzerland and Liechtenstein LAUSANNE, Switzerland, March 15, 2017. Novigenix SA today announced a commercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the early detection of colorectal cancer (CRC).\",\"breadcrumb\":{\"@id\":\"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/colox.ch\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novigenix Signs Distribution Agreement with Dr Risch Medical Laboratory to Access Swiss German Market for Colox\u00ae, its blood based colorectal cancer test\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/colox.ch\/de\/#website\",\"url\":\"https:\/\/colox.ch\/de\/\",\"name\":\"Colox\",\"description\":\"The new generation blood test\",\"publisher\":{\"@id\":\"https:\/\/colox.ch\/de\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/colox.ch\/de\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/colox.ch\/de\/#organization\",\"name\":\"Novigenix SA\",\"url\":\"https:\/\/colox.ch\/de\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png\",\"contentUrl\":\"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png\",\"width\":700,\"height\":297,\"caption\":\"Novigenix SA\"},\"image\":{\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/person\/b62de2e3f97aea1ffe3303259cbbb20a\",\"name\":\"Novigenix\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/colox.ch\/de\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/colox.ch\/wp-content\/uploads\/2017\/09\/Novigenix_avatar-96x96.png\",\"contentUrl\":\"https:\/\/colox.ch\/wp-content\/uploads\/2017\/09\/Novigenix_avatar-96x96.png\",\"caption\":\"Novigenix\"},\"description\":\"Novigenix is an innovative Swiss molecular diagnostics company specializing in new generation blood tests for early detection of cancer. Colox\u00ae, our lead product is a proven molecular blood test designed to significantly reduce mortality from colorectal cancer through early detection and follow-up colonoscopy. Novigenix\u2019s technology is based on a new generation of predictive gene expression profiles of circulating blood cells and concentration profile of tumor-derived protein markers in combination with state-of-the-art mathematical analytical models. Our predictive molecular signatures of biomarkers provide new and accurate solutions for the early detection of cancer.\",\"sameAs\":[\"https:\/\/colox.ch\",\"https:\/\/www.facebook.com\/mymiddlelife\/\"],\"url\":\"https:\/\/colox.ch\/fr\/author\/novigenix\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novigenix Signs Distribution Agreement with Dr Risch Medical Laboratory to Access Swiss German","description":"Agreement significantly increases access to Colox\u00ae in Switzerland and Liechtenstein LAUSANNE, Switzerland, March 15, 2017. Novigenix SA today announced a commercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the early detection of colorectal cancer (CRC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/","og_locale":"fr_FR","og_type":"article","og_title":"Novigenix Signs Distribution Agreement with Dr Risch Medical Laboratory to Access Swiss German","og_description":"Agreement significantly increases access to Colox\u00ae in Switzerland and Liechtenstein LAUSANNE, Switzerland, March 15, 2017. Novigenix SA today announced a commercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the early detection of colorectal cancer (CRC).","og_url":"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/","og_site_name":"Colox","article_author":"https:\/\/www.facebook.com\/mymiddlelife\/","article_published_time":"2017-03-15T09:44:06+00:00","article_modified_time":"2018-03-19T10:43:14+00:00","author":"Novigenix","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Novigenix","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/#article","isPartOf":{"@id":"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/"},"author":{"name":"Novigenix","@id":"https:\/\/colox.ch\/de\/#\/schema\/person\/b62de2e3f97aea1ffe3303259cbbb20a"},"headline":"Novigenix Signs Distribution Agreement with Dr Risch Medical Laboratory to Access Swiss German Market for Colox\u00ae, its blood based colorectal cancer test","datePublished":"2017-03-15T09:44:06+00:00","dateModified":"2018-03-19T10:43:14+00:00","mainEntityOfPage":{"@id":"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/"},"wordCount":581,"commentCount":0,"publisher":{"@id":"https:\/\/colox.ch\/de\/#organization"},"articleSection":["Communiqu\u00e9 de presse"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/","url":"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/","name":"Novigenix Signs Distribution Agreement with Dr Risch Medical Laboratory to Access Swiss German","isPartOf":{"@id":"https:\/\/colox.ch\/de\/#website"},"datePublished":"2017-03-15T09:44:06+00:00","dateModified":"2018-03-19T10:43:14+00:00","description":"Agreement significantly increases access to Colox\u00ae in Switzerland and Liechtenstein LAUSANNE, Switzerland, March 15, 2017. Novigenix SA today announced a commercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the early detection of colorectal cancer (CRC).","breadcrumb":{"@id":"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/colox.ch\/fr\/novigenix-signs-distribution-agreement-with-dr-risch-medical-laboratory-to-access-swiss-german-market-for-colox-its-blood-based-colorectal-cancer-test\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/colox.ch\/"},{"@type":"ListItem","position":2,"name":"Novigenix Signs Distribution Agreement with Dr Risch Medical Laboratory to Access Swiss German Market for Colox\u00ae, its blood based colorectal cancer test"}]},{"@type":"WebSite","@id":"https:\/\/colox.ch\/de\/#website","url":"https:\/\/colox.ch\/de\/","name":"Colox","description":"The new generation blood test","publisher":{"@id":"https:\/\/colox.ch\/de\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/colox.ch\/de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/colox.ch\/de\/#organization","name":"Novigenix SA","url":"https:\/\/colox.ch\/de\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/","url":"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png","contentUrl":"http:\/\/colox.ch\/wp-content\/uploads\/2017\/04\/logo_novigenix-negatif-700px-2.png","width":700,"height":297,"caption":"Novigenix SA"},"image":{"@id":"https:\/\/colox.ch\/de\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/colox.ch\/de\/#\/schema\/person\/b62de2e3f97aea1ffe3303259cbbb20a","name":"Novigenix","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/colox.ch\/de\/#\/schema\/person\/image\/","url":"https:\/\/colox.ch\/wp-content\/uploads\/2017\/09\/Novigenix_avatar-96x96.png","contentUrl":"https:\/\/colox.ch\/wp-content\/uploads\/2017\/09\/Novigenix_avatar-96x96.png","caption":"Novigenix"},"description":"Novigenix is an innovative Swiss molecular diagnostics company specializing in new generation blood tests for early detection of cancer. Colox\u00ae, our lead product is a proven molecular blood test designed to significantly reduce mortality from colorectal cancer through early detection and follow-up colonoscopy. Novigenix\u2019s technology is based on a new generation of predictive gene expression profiles of circulating blood cells and concentration profile of tumor-derived protein markers in combination with state-of-the-art mathematical analytical models. Our predictive molecular signatures of biomarkers provide new and accurate solutions for the early detection of cancer.","sameAs":["https:\/\/colox.ch","https:\/\/www.facebook.com\/mymiddlelife\/"],"url":"https:\/\/colox.ch\/fr\/author\/novigenix\/"}]}},"_links":{"self":[{"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/posts\/1703"}],"collection":[{"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/comments?post=1703"}],"version-history":[{"count":0,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/posts\/1703\/revisions"}],"wp:attachment":[{"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/media?parent=1703"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/categories?post=1703"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/colox.ch\/fr\/wp-json\/wp\/v2\/tags?post=1703"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}